covid
Buscar en
Endocrinología y Nutrición (English Edition)
Toda la web
Inicio Endocrinología y Nutrición (English Edition) BRAFT1799A mutation in the primary tumor as a marker of risk, recurrence, or per...
Información de la revista
Vol. 58. Núm. 4.
Páginas 175-184 (abril 2011)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 58. Núm. 4.
Páginas 175-184 (abril 2011)
Original article
Acceso a texto completo
BRAFT1799A mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma
Presencia de la mutación BRAFT1799A en el tumor primario como indicador de riesgo, recidiva o persistencia de carcinoma papilar de tiroides
Visitas
1404
Marisa Cañadas Garrea,
Autor para correspondencia
marisacgarre@gmail.com

Corresponding author.
, Martín López de la Torre Casaresb, Patricia Becerra Massarec, Miguel Ángel López Nevotd, Jesús Villar Del Morale, Nuria Muñoz Péreze, Ricardo Vílchez Joyab, Rosa Montes Ramírezf, José Manuel Llamas Elviraa
a Servicio de Medicina Nuclear, Hospital Universitario Virgen de las Nieves, Granada, Spain
b Servicio de Endocrinología, Hospital Universitario Virgen de las Nieves, Granada, Spain
c Servicio de Anatomía Patológica, Hospital Universitario Virgen de las Nieves, Granada, Spain
d Servicio de Análisis Clínicos, Hospital Universitario Virgen de las Nieves, Granada, Spain
e Servicio de Cirugía General y del Aparato Digestivo, Hospital Universitario Virgen de las Nieves, Granada, Spain
f Departamento de Fisiología, Universidad de Granada, Spain
Este artículo ha recibido
Información del artículo
Abstract
Background and objective

The BRAFT1799A mutation is reported to be associated with aggressive, persistent, and recurrent tumor in patients with papillary thyroid carcinoma (PTC). The association of the BRAFT1799A mutation in the primary tumor with the clinicopathological characteristics of PTC was analyzed.

Patients, materials, and methods

Ninety-seven PTC patients were followed up for a median of 64.1 months. The BRAFT1799A mutation was analyzed in DNA from initial thyroidectomy biopsies by PCR amplification and restriction fragment length polymorphism using the TspRI enzyme. Positive results were confirmed by DNA sequencing. The statistical association of the BRAFT1799A mutation and clinicopathological characteristics was analyzed using the relevant hypothesis tests and logistic regression.

Results

The BRAFT1799A mutation was found in 46.4% of patients. Bivariate and multivariate analyses showed the mutation to be only associated with age over 60 years (odds ratio [OR]=5.5; 95% confidence interval [CI], 1.4–21.9; p=0.019) and to a tumor size of 1cm or greater (OR=3.6, 95% CI, 1.2–10.3; p=0.016). The mutation was not associated with histological subtype, metastasis, recurrence, more aggressive treatments (131I ablation therapy or other surgery), or PTC persistence at the end of follow-up.

Conclusions

The BRAFT1799A mutation is associated with age over 60 and a tumor size of 1cm or greater, but not with other clinicopathological characteristics, tumor recurrence, or PTC persistence.

Keywords:
BRAFT1799A mutation
Papillary thyroid carcinoma
Tumor recurrence
Resumen
Antecedentes y objetivo

La mutación BRAFT1799A se ha relacionado con características tumorales de más agresividad, recidiva tumoral y persistencia de carcinoma papilar de tiroides (CPT), aunque no todos los estudios apoyan esta asociación. En éste, se analiza la asociación entre la presencia de la mutación BRAFT1799A en el tumor primario de pacientes con CPT y las características clinicopatológicas de riesgo, recidiva y persistencia tumoral.

Pacientes, material y método

Hemos seguido a 97 pacientes intervenidos de CPT durante una mediana de 64,1 meses. La mutación BRAFT1799A se determinó en ácido desoxirribonucleico procedente de muestras de la tiroidectomía inicial mediante amplificación por PCR del exón 15 del gen braf y análisis de los fragmentos de restricción con la enzima TspRI. Los casos positivos fueron confirmados por secuenciación. La asociación estadística entre la mutación BRAFT1799A y las diferentes variables se estudió mediante los correspondientes tests de contraste de hipótesis más regresión logística.

Resultados

El 46,4% de los pacientes eran positivos para la mutación BRAFT1799A. Tras análisis bivariante y multivariante, la mutación BRAFT1799A sólo se asociaba con edad superior a 60 años (odds ratio [OR]=5,5; intervalo de confianza [IC] del 95%, 1,4–21,9; p=0,019) y tamaño de 1cm o superior (OR=3,6; IC del 95%, 1,2–10,3; p=0,016). No se asociaba con subtipos histológicos, metástasis, recidiva, necesidad de nuevos tratamientos ablativos con I131 o de otras intervenciones quirúrgicas debidas a la aparición de metástasis o persistencia de enfermedad al final del seguimiento.

Conclusiones

La mutación BRAFT1799A está asociada a edad superior a 60 años y tamaño tumoral de 1cm o mayor, pero no con otras características clinicopatológicas, recidiva tumoral o persistencia de enfermedad.

Palabras clave:
Mutación BRAFT1799A
Carcinoma papilar de tiroides
Recidiva tumoral
El Texto completo está disponible en PDF
References
[1.]
National Cancer Institute [portal en internet]. Bethesda, MD;SEER Cancer Statistics Review, 1975–2007 [update 2010; cited 2010 Sept 16]. Available from: http://seer.cancer.gov/statfacts/html/thyro.html#incidence-mortality.
[2.]
A.Y. Chen, A. Jemal, E.M. Ward.
Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005.
Cancer, 115 (2009), pp. 3801-3807
[3.]
S.A. Hundahl, I.D. Fleming, A.M. Fremgen, H.R. Menck.
A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995.
Cancer, 83 (1998), pp. 2638-2648
[4.]
E.L. Mazzaferri, R.T. Kloos.
Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer.
J Clin Endocrinol Metab, 86 (2001), pp. 1447-1463
[5.]
L. Duntas, B.M. Grab-Duntas.
Risk and prognostic factors for differentiated thyroid cancer.
Hell J Nucl Med, 9 (2006), pp. 156-162
[6.]
C. Zafon, G. Obiols.
Vía de señalización dependiente de la proteincinasa de activación mitogénica en el carcinoma papilar de tiroides. De las bases moleculares a la práctica clínica.
Endocrinol Nutr., 56 (2009), pp. 176-186
[7.]
H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, et al.
Mutations of the BRAF gene in human cancer.
Nature, 417 (2002), pp. 949-954
[8.]
M. Xing.
BRAF mutation in thyroid cancer.
Endocr Relat Cancer, 12 (2005), pp. 245-262
[9.]
M. Xing.
BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications.
Endocr Rev, 28 (2007), pp. 742-762
[10.]
S. Lassalle, V. Hofman, M. Ilie, C. Butori, A. Bozec, J. Santini, et al.
Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.
Curr Med Chem, 17 (2010), pp. 1839-1850
[11.]
G. Riesco-Eizaguirre, P. Gutiérrez-Martínez, M.A. García-Cabezas, M. Nistal, P. Santisteban.
The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane.
Endocr Relat Cancer, 13 (2006), pp. 257-269
[12.]
E. Puxeddu, S. Moretti.
Clinical prognosis in BRAF-mutated PTC.
Arq Bras Endocrinol Metabol, 51 (2007), pp. 736-747
[13.]
Y. Cohen, N. Goldenberg-Cohen, P. Parrella, I. Chowers, S.L. Merbs, J. Pe’er, et al.
Lack of BRAF mutation in primary uveal melanoma.
Invest Ophthalmol Vis Sci, 44 (2003), pp. 2876-2878
[14.]
Y. Cohen, M. Xing, E. Mambo, Z. Guo, G. Wu, B. Trink, et al.
BRAF mutation in papillary thyroid carcinoma.
J Natl Cancer Inst, 95 (2003), pp. 625-627
[15.]
J.H. Lee, E.S. Lee, Y.S. Kim.
Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a metaanalysis.
Cancer, 110 (2007), pp. 38-46
[16.]
E. Kebebew, J. Weng, J. Bauer, G. Ranvier, O.H. Clark, Q.Y. Duh, et al.
The prevalence and prognostic value of BRAF mutation in thyroid cancer.
Ann Surg, 246 (2007), pp. 466-470
[17.]
F. Basolo, L. Torregrossa, R. Giannini, M. Miccoli, C. Lupi, E. Sensi, et al.
Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases.
J Clin Endocrinol Metab, 95 (2010), pp. 4197-4205
[18.]
C. Lupi, R. Giannini, C. Ugolini, A. Proietti, P. Berti, M. Minuto, et al.
Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.
J Clin Endocrinol Metab, 92 (2007), pp. 4085-4090
[19.]
M. Xing, W.H. Westra, R.P. Tufano, Y. Cohen, E. Rosenbaum, K.J. Rhoden, et al.
BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer.
J Clin Endocrinol Metab, 90 (2005), pp. 6373-6379
[20.]
G. Oler, J.M. Cerutti.
High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.
Cancer, 115 (2009), pp. 972-980
[21.]
A.M. Costa, A. Herrero, M.F. Fresno, J. Heymann, J.A. Alvarez, J. Cameselle-Teijeiro, et al.
BRAF mutation associated with other genetic events identifies a subset of aggressive papillary thyroid carcinoma.
Clin Endocrinol (Oxf), 68 (2008), pp. 618-634
[22.]
S.A. Hundahl, B. Cady, M.P. Cunningham, E. Mazzaferri, R.F. McKee, J. Rosai, et al.
Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation study.
Cancer, 89 (2000), pp. 202-217
[23.]
A. Rouxel, G. Hejblum, M.O. Bernier, P.Y. Boëlle, F. Ménégaux, G. Mansour, et al.
Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas.
J Clin Endocrinol Metab, 89 (2004), pp. 5362-5368
[24.]
M. Xing, D. Clark, H. Guan, M. Ji, A. Dackiw, K.A. Carson, et al.
BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.
J Clin Oncol, 27 (2009), pp. 2977-2982
[25.]
R. Elisei, C. Ugolini, D. Viola, C. Lupi, A. Biagini, R. Giannini, et al.
BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study.
J Clin Endocrinol Metab, 93 (2008), pp. 3943-3949
[26.]
T.Y. Kim, W.B. Kim, Y.S. Rhee, J.Y. Song, J.M. Kim, G. Gong, et al.
The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma.
Clin Endocrinol (Oxf), 65 (2006), pp. 364-368
[27.]
M. Xing.
Prognostic utility of BRAF mutation in papillary thyroid cancer.
Mol Cell Endocrinol, 321 (2010), pp. 86-93
[28.]
L. Fugazzola, E. Puxeddu, N. Avenia, C. Romei, V. Cirello, A. Cavaliere, et al.
Correlation between B-RAFV600E mutation and clinicopathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature.
Endocr Relat Cancer, 13 (2006), pp. 455-464
[29.]
D.S. Cooper, G.M. Doherty, B.R. Haugen, R.T. Kloos, S.L. Lee, S.L. Mandel, et al.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
Thyroid, 19 (2009), pp. 1167-1214
[30.]
K.B. Ain.
Management of undifferentiated thyroid cancer.
Baillières Best Pract Res Clin Endocrinol Metab, 14 (2000), pp. 615-629
Copyright © 2011. Sociedad Española de Endocrinología y Nutrición
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos